Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin therapy for treatment-resistant depression (single-arm, open-label, Japan)
jRCTs031230351Completed
- Sponsor
- SENSHIN Medical Research Foundation
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of psilocybin in treatment-resistant depression (TRD), sponsored by SENSHIN Medical Research Foundation. Primary endpoint: Completion rate of two courses of psilocybin therapy. Started Nov 2024; status: completed.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on jRCTs031230351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230351.